Thus, agents that promote the nuclear export of HDAC5 from the Pkd1–/–cell nucleus and, thus, de-repress MEF2C target genes should have therapeutic potential for treating ADPKD. Here, PKD1 is linked to autosomal dominant polycystic kidney disease.